|
1
|
Costentin C: Hepatocellular carcinoma
surveillance. Presse Med. 46:381–385. 2017.In French. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alsaied OA, Sangwan V, Banerjee S, Krosch
TC, Chugh R, Saluja A, Vickers SM and Jensen EH: Sorafenib and
triptolide as combination therapy for hepatocellular carcinoma.
Surgery. 156:270–279. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu ZX, Huang JW, Liao MH and Zeng Y:
Treatment strategy for hepatocellular carcinoma in China:
Radiofrequency ablation versus liver resection. Jpn J Clin Oncol.
46:1075–1080. 2016.PubMed/NCBI
|
|
4
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y, Huang F, Wang J, Peng L and Luo
H: MiR-15b mediates liver cancer cells proliferation through
targeting BCL-2. Int J Clin Exp Pathol. 8:15677–15683. 2015.
|
|
6
|
Liu CY, Chen KF and Chen PJ: Treatment of
liver cancer. Cold Spring Harb Perspect Med. 5:a0215352015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Llovet JM, Schwartz M and Mazzaferro V:
Resection and liver transplantation for hepatocellular carcinoma.
Semin Liver Dis. 25:181–200. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo M, Zhang H, Zheng J and Liu Y:
Glypican-3: A new target for diagnosis and treatment of
hepatocellular carcinoma. J Cancer. 11:2008–2021. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balcerak A, Trebinska-Stryjewska A, Wakula
M, Chmielarczyk M, Smietanka U, Rubel T, Konopinski R,
Macech-Klicka E, Zub R and Grzybowska EA: HAX1 impact on collective
cell migration, cell adhesion, and cell shape is linked to the
regulation of actomyosin contractility. Mol Biol Cell.
30:3024–3036. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bidwell PA, Liu GS, Nagarajan N, Lam CK,
Haghighi K, Gardner G, Cai WF, Zhao W, Mugge L, Vafiadaki E, et al:
HAX-1 regulates SERCA2a oxidation and degradation. J Mol Cell
Cardiol. 114:220–233. 2018. View Article : Google Scholar :
|
|
11
|
Fadeel B and Grzybowska E: HAX-1: A
multifunctional protein with emerging roles in human disease.
Biochim Biophys Acta. 1790:1139–1148. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wei XJ, Li SY, Yu B, Chen G, Du JF and Cai
HY: Expression of HAX-1 in human colorectal cancer and its clinical
significance. Tumour Biol. 35:1411–1415. 2014. View Article : Google Scholar
|
|
13
|
Li X, Li T, You B, Shan Y, Shi S, Cao X
and Qian L: Expression and function of HAX-1 in human cutaneous
squamous cell carcinoma. J Cancer. 6:351–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
You Y, Yao H, You B, Li X, Ni H, Shi S,
Shan Y and Cao X: Clinical significance of HAX-1 expression in
laryngeal carcinoma. Auris Nasus Larynx. 42:299–304. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Feng X, Kwiecinska A, Rossmann E, Bottai
M, Ishikawa T, Patarroyo M, Österborg A, Porwit A, Zheng C and
Fadeel B: HAX-1 overexpression in multiple myeloma is associated
with poor survival. Br J Haematol. 185:179–183. 2019. View Article : Google Scholar
|
|
16
|
Ramsay AG, Keppler MD, Jazayeri M, Thomas
GJ, Parsons M, Violette S, Weinreb P, Hart IR and Marshall JF:
HS1-associated protein X-1 regulates carcinoma cell migration and
invasion via clathrin-mediated endocytosis of integrin alphavbeta6.
Cancer Res. 67:5275–5284. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Y, Huo X, Cao Z, Xu H, Zhu J, Qian L,
Fu H and Xu B: HAX-1 is overexpressed in hepatocellular carcinoma
and promotes cell proliferation. Int J Clin Exp Pathol.
8:8099–8106. 2015.PubMed/NCBI
|
|
18
|
Banerjee A, Saito K, Meyer K, Banerjee S,
Ait-Goughoulte M, Ray RB and Ray R: Hepatitis C virus core protein
and cellular protein HAX-1 promote 5-fluorouracil-mediated
hepatocyte growth inhibition. J Virol. 83:9663–9671. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu W, Cui Z and Zan X: Identifying
cancer-related microRNAs based on subpathways. IET Syst Biol.
12:273–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gandhi NS, Tekade RK and Chougule MB:
Nanocarrier mediated delivery of siRNA/miRNA in combination with
chemotherapeutic agents for cancer therapy: Current progress and
advances. J Control Release. 194:238–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gallach S, Calabuig-Farinas S,
Jantus-Lewintre E and Camps C: MicroRNAs: Promising new
antiangiogenic targets in cancer. Biomed Res Int. 2014:8784502014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li E, Ji P, Ouyang N, Zhang Y, Wang XY,
Rubin DC, Davidson NO, Bergamaschi R, Shroyer KR, Burke S, et al:
Differential expression of miRNAs in colon cancer between African
and Caucasian Americans: Implications for cancer racial health
disparities. Int J Oncol. 45:587–594. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishida N, Mimori K, Fabbri M, Yokobori T,
Sudo T, Tanaka F, Shibata K, Ishii H, Doki Y and Mori M:
MicroRNA-125a-5p is an independent prognostic factor in gastric
cancer and inhibits the proliferation of human gastric cancer cells
in combination with trastuzumab. Clin Cancer Res. 17:2725–2733.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li G, Zhang W, Gong L and Huang X:
MicroRNA 125a-5p inhibits cell proliferation and induces apoptosis
in hepatitis B virus-related hepatocellular carcinoma by
downregulation of ErbB3. Oncol Res. 27:449–458. 2019. View Article : Google Scholar
|
|
26
|
Cai M, Chen Q, Shen J, Lv C and Cai L:
Epigenetic silenced miR-125a-5p could be self-activated through
targeting Suv39H1 in gastric cancer. J Cell Mol Med. 22:4721–4731.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bi Q, Tang S, Xia L, Du R, Fan R, Gao L,
Jin J, Liang S, Chen Z, Xu G, et al: Ectopic expression of MiR-125a
inhibits the proliferation and metastasis of hepatocellular
carcinoma by targeting MMP11 and VEGF. PLoS One. 7:e401692012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Menyhárt O, Nagy Á and Győrffy B:
Determining consistent prognostic biomarkers of overall survival
and vascular invasion in hepatocellular carcinoma. R Soc Open Sci.
5:1810062018. View Article : Google Scholar
|
|
29
|
Ke Q, Ji J, Cheng C, Zhang Y, Lu M, Wang
Y, Zhang L, Li P, Cui X, Chen L, et al: Expression and prognostic
role of Spy1 as a novel cell cycle protein in hepatocellular
carcinoma. . Exp Mol Pathol. 87:167–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
31
|
Sheng C and Ni Q: Expression of HAX1 and
Ki-67 in breast cancer and its correlations with patient's
clinicopathological characteristics and prognosis. Int J Clin Exp
Med. 8:20904–20910. 2015.
|
|
32
|
Li M, Tang Y, Zang W, Xuan X, Wang N, Ma
Y, Wang Y, Dong Z and Zhao G: Analysis of HAX-1 gene expression in
esophageal squamous cell carcinoma. Diagn Pathol.
8:472013.PubMed/NCBI
|
|
33
|
Deng X, Song L, Wei Y and Guo XB: Analysis
of the expression of HAX-1 gene in human glioma. Neurosci Lett.
657:189–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu Z, Ai X, Hu H, Wang S, Wang Y, Kang F,
Ouyang C and Zhu J: Hematopoietic-substrate-1 associated protein
X-1 (HAX-1) regulates liver cancer cells growth, metastasis, and
angiogenesis through Akt. Cancer Biol Ther. 20:1223–1233. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kramer N, Walzl A, Unger C, Rosner M,
Krupitza G, Hengstschläger M and Dolznig H: In vitro cell migration
and invasion assays. Mutat Res. 752:10–24. 2013. View Article : Google Scholar
|
|
36
|
Duff D and Long A: Roles for RACK1 in
cancer cell migration and invasion. Cell Signal. 35:250–255. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hua L, Wang CY, Yao KH, Chen JT, Zhang JJ
and Ma WL: High expression of long non-coding RNA ANRIL is
associated with poor prognosis in hepatocellular carcinoma. Int J
Clin Exp Pathol. 8:3076–3082. 2015.PubMed/NCBI
|
|
38
|
Shan H, Zhou X and Chen C: MicroRNA214
suppresses the viability, migration and invasion of human
colorectal carcinoma cells via targeting transglutaminase 2. Mol
Med Rep. 20:1459–1467. 2019.PubMed/NCBI
|
|
39
|
Yan L, Yu MC, Gao GL, Liang HW, Zhou XY,
Zhu ZT, Zhang CY, Wang YB and Chen X: MiR-125a-5p functions as a
tumour suppressor in breast cancer by downregulating BAP1. J Cell
Biochem. 119:8773–8783. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang X, Qiu J, Kang H, Wang Y and Qian J:
miR-125a-5p suppresses colorectal cancer progression by targeting
VEGFA. Cancer Manag Res. 10:5839–5853. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang Y, Zhang D, Lv J, Wang S and Zhang
Q: MiR-125a-5p suppresses bladder cancer progression through
targeting FUT4. Biomed Pharmacother. 108:1039–1047. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhong L, Sun S, Shi J, Cao F, Han X and
Chen Z: MicroRNA-125a-5p plays a role as a tumor suppressor in lung
carcinoma cells by directly targeting STAT3. Tumour Biol.
39:10104283176975792017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Fu Y and Cao F: MicroRNA-125a-5p regulates
cancer cell proliferation and migration through NAIF1 in prostate
carcinoma. Onco Targets Ther. 8:3827–3835. 2015. View Article : Google Scholar
|
|
44
|
Tang L, Zhou L, Wu S, Shi X, Jiang G, Niu
S and Ding D: miR-125a-5p inhibits colorectal cancer cell
epithelial-mesenchymal transition, invasion and migration by
targeting TAZ. Onco Targets Ther. 12:3481–3489. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qin X, Wan Y, Wang S and Xue M:
MicroRNA-125a-5p modulates human cervical carcinoma proliferation
and migration by targeting ABL2. Drug Des Devel Ther. 10:71–79.
2015.
|
|
46
|
Potenza N, Mosca N, Zappavigna S,
Castiello F, Panella M, Ferri C, Vanacore D, Giordano A, Stiuso P,
Caraglia M and Russo A: MicroRNA-125a-5p is a downstream effector
of sorafenib in its antiproliferative activity toward human
hepato-cellular carcinoma cells. J Cell Physiol. 232:1907–1913.
2017. View Article : Google Scholar
|
|
47
|
Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ,
Kim MG, Chang YG, Shen Q, Park WS, Lee JY, et al: Sirtuin7
oncogenic potential in human hepatocellular carcinoma and its
regulation by the tumor suppressors MiR-125a-5p and MiR-125b.
Hepatology. 57:1055–1067. 2013. View Article : Google Scholar
|
|
48
|
Yu YF, Zhang Y, Shen N, Zhang RY and Lu
XQ: Effect of VEGF, P53 and telomerase on angiogenesis of gastric
carcinoma tissue. Asian Pac J Trop Med. 7:293–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhou X, Wu W, Zeng A, Nie E, Jin X, Yu T,
Zhi T, Jiang K, Wang Y, Zhang J and You Y: MicroRNA-141-3p promotes
glioma cell growth and temozolomide resistance by directly
targeting p53. Oncotarget. 8:71080–71094. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Leung DW, Cachianes G, Kuang WJ, Goeddel
DV and Ferrara N: Vascular endothelial growth factor is a secreted
angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhang T, Liu M, Wang C, Lin C, Sun Y and
Jin D: Down-regulation of MiR-206-promotes proliferation and
invasion of laryngeal cancer by regulating VEGF expression.
Anticancer Res. 31:3859–3863. 2011.PubMed/NCBI
|
|
53
|
Wu QB, Chen J, Zhu JW, Yin X, You HY, Lin
YR and Zhu HQ: MicroRNA-125 inhibits RKO colorectal cancer cell
growth by targeting VEGF. Int J Mol Med. 42:665–673.
2018.PubMed/NCBI
|
|
54
|
Jakobsen KR, Demuth C, Sorensen BS and
Nielsen AL: The role of epithelial to mesenchymal transition in
resistance to epidermal growth factor receptor tyrosine kinase
inhibitors in non-small cell lung cancer. Transl Lung Cancer Res.
5:172–182. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Xiao Z, Chen M, Yang J, Yang C, Lü X, Tian
H and Liu C: MTBP regulates migration and invasion of prostate
cancer cells in vitro. Nan Fang Yi Ke Da Xue Xue Bao. 39:6–12.
2019.In Chinese. PubMed/NCBI
|
|
56
|
Ramamurthy VP, Ramalingam S, Gediya LK and
Njar VCO: The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E
signaling pathways to suppress EMT and castration-resistant
prostate cancer xenograft growth. FEBS J. 285:1051–1063. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
